Opinion

Harold Burstein and Thomas Grinda

Nov 15, 2024, 16:18

Erika Hamilton: Harold Burstein and Thomas Grinda on anthracyline use in early breast cancer

Erika Hamilton, the Director of Breast Cancer Program at Sarah Cannon Research Institute, shared on LinkedIn:

“Harold Burstein and Thomas Grinda have a very thoughtful commentary in Journal of Clinical Oncology re: anthracyline use in early breast cancer.

They argue that there is still a role in TNBC and locally advanced HR+ for additional risk reduction, but little to no role for HER2 Breast Cancer any longer. Have to agree with this wholeheartedly.

My favorite quote (that sounds quite a lot like Harold Burstein might I add):

“Owing to the relentless math of proportional risk reduction and absolute risk of recurrence, improvements achieved through these nonanthracycline treatment enhancements mean that any residual clinical benefits from anthracyclines are becoming progressively narrower.”

Anthracyclines in Early Breast Cancer: The Long Goodbye

Authors: Thomas Grinda, and Harold J. Burstein

Erika Hamilton: Harold Burstein and Thomas Grinda on anthracyline use in early breast cancer

More posts featuring Erika Hamilton

Erika Hamilton is a medical oncologist and the Director of Breast Cancer Program at Sarah Cannon Research Institute (USA). Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee. She is active in the community, volunteering with Gilda’s Club Middle Tennessee, the American Cancer Society’s Hope Lodge, Ovarcome ovarian cancer support organization, Brentwood Baptist Church and the Susan G. Komen Race for the Cure.